NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales fell 11 percent in Swiss francs for the nine months ended Sept. 30, but increased 3 percent at constant exchange rates.
The Swiss pharmaceuticals, diagnostics, and research products giant brought in molecular diagnostics revenues of CHF801 million for the first nine months of the year compared to CHF900 million for the first nine months of 2010. It said that its molecular tests for HIV and hepatitis B virus viral load were the main sales drivers for the business.
Its applied science sales declined 16 percent in Swiss francs to CHF544 million from CHF646 million. At constant exchange rates, the applied science business was down 2 percent year over year. "Sales continue to be impacted by the year-on-year decline in H1N1 influenza testing, increasing competition in gene sequencing, and flat research funding," Roche said in a statement.
Its tissue diagnostics business reported a 3 percent decline in sales to CHF382 million from CHF393 million. At constant exchange rates, its revenues increased 15 percent.
Overall, Roche's diagnostics revenues fell to CHF7.10 billion from CHF7.73 billion, down 8 percent in Swiss francs, but up 6 percent at constant exchange rates.
The Roche Group posted total revenues of CHF31.49 billion for the nine-month period, down from CHF36.13 billion for the comparable period of 2010. At constant exchange rates, sales were up 6 percent.